Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCMH7O)

Drug Name

JNJ-28312141 Drug Info

Synonyms

JNJ 28312141

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CSF1R messenger RNA (CSF1R mRNA)	TTVW6QL	CSF1R_HUMAN	Inhibitor	[2]
Fms-like tyrosine kinase 3 (FLT-3)	TTGJCWZ	FLT3_HUMAN	Inhibitor	[1]
LCK tyrosine protein kinase (LCK)	TT860QF	LCK_HUMAN	Inhibitor	[1]
NT-3 growth factor receptor (TrkC)	TTXABCW	NTRK3_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
NT-3 growth factor receptor (TrkC)	DTT	NTRK3	7.27	6.435	6.1	6.863
Tyrosine-protein kinase Kit (KIT)	DTT	KIT	3.766	7.517	7.379	6.916
CSF1R messenger RNA (CSF1R mRNA)	DTT	CSF1R	7.727	7.423	6.924	7.156
LCK tyrosine protein kinase (LCK)	DTT	LCK	5.2	4.443	4.53	6.325

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Discovery agent

ICD Disease Classification

N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
NT-3 growth factor receptor (TrkC)	DTT	NTRK3	7.06E-04	-0.14	-0.43
Tyrosine-protein kinase Kit (KIT)	DTT	KIT	2.06E-01	-0.1	-0.14
CSF1R messenger RNA (CSF1R mRNA)	DTT	CSF1R	1.99E-05	0.39	0.56
Fms-like tyrosine kinase 3 (FLT-3)	DTT	FLT3	2.11E-01	-0.05	-0.16

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61.
2	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.